重组人血管内皮抑制素注射液联合化疗治疗晚期胃癌合并恶性腹水的临床疗效及对患者生活质量的影响  

Clinical efficacy of recombinant human endostatin injection combined with chemotherapy in the treatment of ;patients with advanced gastric cancer and its influence on the quality of life

作　　者：金剑英[1] 郭群[1] 王峥嵘[1] 谢静静[1] 金丹[1] 

机构地区：[1]浙江省台州医院肿瘤内科,浙江省台州317000

出　　处：《中国基层医药》2016年第19期2881-2885,共5页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：探讨重组人血管内皮抑制素注射液联合化疗治疗晚期胃癌合并恶性腹水患者的临床疗效及对患者生活质量的影响。方法选择2012年7月至2015年7月收治的晚期胃癌合并恶性腹水患者62例，按照数字表法随机分为观察组31例与对照组31例。对照组采用 FOLFOX6化疗方案治疗，观察组在对照组基础上联合重组人血管内皮抑制素注射液治疗。两组疗程均为3周。比较两组近期疗效，治疗前后QOL 评分、Karnofsky 评分、血清 CEA 和 CA19-9水平变化及用药期间毒副反应发生情况。结果观察组有效率（54．84％）高于对照组（29．03％）（χ2＝4．2393，P ＜0．05）；两组 QOL 评分和 Karnofsky 评分治疗后明显增加（P ＜0．05）；观察组 QOL 评分和 Karnofsky 评分治疗后高于对照组（t ＝6．5127、5．6690，均 P ＜0．05）；两组血清 CEA 和 CA19-9水平治疗后明显降低（P ＜0．05）；观察组血清 CEA 和 CA19-9水平治疗后均低于对照组（t ＝5．2760、6．3108，均 P ＜0．05）；两组白细胞减少、血小板减少、周围神经毒性、血红蛋白减少、腹泻、恶心呕吐不良反应发生率差异无统计学意义（P ＞0．05）。结论重组人血管内皮抑制素注射液联合化疗治疗晚期胃癌合并恶性腹水患者的临床疗效显著，且可明显提高患者生活质量，具有重要研究价值。Objective To explore the clinical curative effect of recombinant human endostatin injection combined with chemotherapy in the treatment of patients with advanced gastric cancer and malignant ascites,and its influence on the quality of life.Methods 62 patients with advanced gastric cancer from July 2012 to July 2015,were randomly divided into observation group （31 cases）and control group （31 cases）.The control group was treated with FOLFOX6 chemotherapy,the observation group was given recombinant human endostatin injection on the basis of the treatment of the control group.The two groups were treated for 3 weeks.The curative effect,QOL score,Karnofsky score,the change of serum CEA and CA19 -9 levels and drug adverse reaction incidence before and after treatment were compared in the two groups.Results The RR of the observation group was higher than that of the control group （54.84 vs 29.03%,χ2 =4.239 3,P 〈0.05）.The QOL score and Karnofsky score in the two groups were increased after treatment （P 〈0.05）.The QOL score and Karnofsky score after treatment in the observation group were higher than the control group（t =6.512 7,5.669 0,all P 〈0.05）.The serum CEA and CA19 -9 levels of the two groups decreased significantly after treatment （P 〈0.05）.The serum CEA and CA19 -9 levels of the observation group were lower than the control group after treatment （t =5.276 0,6.310 8,all P 〈0.05）.The leukopenia,thrombocytopenia, peripheral neurotoxicity,decreased hemoglobin,diarrhea,nausea and vomiting adverse reaction rate of the two groups had no significant differences （P 〉0.05）.Conclusion The clinical efficacy of recombinant human endostatin injec-tion combined with malignant ascites in the treatment of patients with advanced gastric carcinoma is significant,and can significantly improve the quality of life of patients,has the important research value.

关 键 词：重组人血管内皮抑制素注射液 化学治疗 胃肿瘤 恶性腹水 治疗效果 生活质量 

分 类 号：R735.2[医药卫生—肿瘤]